Successful Treatment of Cutaneous Mucormycosis after Renal Transplantation by Debridement, Liposomal Amphotericin B, and Isavuconazole
Indian Journal of Transplantation · 2023-10 · 17 (4) · 470-471
DOI: 10.4103/ijot.ijot_67_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Transplantation, online erschienen am 29.12.2023. Verfasst von Balaji Kirushnan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Dear Editor, Mr. C aged 56 years is a known patient of diabetes mellitus on insulin, hypertension, chronic kidney disease V, and nonvalvular atrial fibrillation was on regular hemodialysis three times a week. He had a history of thrombotic stroke with left-sided hemiparesis. He received deceased donor renal transplant on October 17, 2021. Donor was a 33-year-old male patient with same B blood group. The donor was not a diabetic or hypertensive and was a victim of road traffic accident with subarachnoid hemorrhage. In view of elevated total counts, blood and urine cultures were sent before organ harvesting. The donor had evidence of oral candidiasis. Donor had normal creatinine at the time of organ harvest with the urine output of 50 mL/h. The Centers for Disease Control and Prevention cross-match was negative. Reverse transcription-polymerase chain reaction COVID-19 was negative for the donor. The left kidney was received for transplant with single artery and single vein. Injection antilymphocyte globulin 3 mg/kg (200 mg) was give as induction agent. The total ischemia time was 2 h and 10 min as this was an in house deceased donor renal transplant. Kidney became Pink and turgid after anastomosis. There was immediate urine output after clamp release. DJ stent was placed. Methylprednisolone 500 mg intravenous (IV) was given intraoperatively. Postoperatively, he had good urine output and creatinine gradually improved to 1.3 mg% after 8 days. He received the 2nd dose of injection ALG 200 mg on day 4 posttransplant. Tacrolimus level as 6.1 on the postoperative day 6. Ultrasonography Doppler showed resistive index of 0.7 with good arterial and venous flow. There was no perigraft collection. Recipient was on IV Cefoperazone sulbactam 1.5 g IV twice a day and IV fluconazole 400 mg IV once a day. He received triple immunosuppression as per the protocol. Donor cultures were followed, and it was sterile. He was discharged after 13 days with triple immunosuppression, valganciclovir 450 mg/day and co-trimoxazole 160/800 mg once a day. Sugars were controlled with insulin. He had normal graft function. On the postoperative day 13, he had discharge from the wound site. There was no fever or pain over the graft site. Wound infection was suspected, and wound discharge was sent for culture sensitivity. He was started on oral amoxicillin and clavulanic acid 625 mg twice a day. After 5 days, there was no improvement in the wound discharge with spread to the adjacent areas which required alternate suture removal. (a) Investigations showed elevated total count of 23,000. He was admitted for IV antibiotics and daily dressings. Blood culture and wound swab culture were sent. Pus was sent for acid-fast bacilli, fungal stain, and fungal culture in view of rapid spread of the wound. The patient was continued on antibiotics. Lactophenol cotton blue stain demonstrated broad nonseptate or sparsely septate fungi suggestive of mucormycosis. (b) After 48 h of hospitalization, there was a growth of white cottony fungal suggestive of mucormycosis. (c) The patient was started on IV liposomal amphotericin B 5 mg/kg/day for 14 days. Plastic surgery advised regular dressing and split skin grafting later. Oral isavuconazole 200 mg every 8th hourly for 3 days followed by once a day for 21 days were given. The patient did not have fluctuation in creatinine levels and tacrolimus level was 6 ng/mL after 1 week of isavuconazole. After the 3rd debridement, there was only 1 cm gap between the graft and ulcer bed. There was no graft involvement. Computed tomography (CT) abdomen confirmed a gap between the ulcer bed and the kidney. (d) Repeat tacrolimus level after 2 weeks of isavuconazle was 5.5 ng/mL. One and half months after transplant, the patient underwent split skin grafting from the left thigh. There was a good uptake of the graft and creatinine was 1.1 after 2 months (e) [Figure 1].Figure 1: Clinical, microbiological and radiological image of the case. (a) Necrotic blackish wound over the surgical site, (b) Lactophenol cotton blue stain demonstrating Mucor species, (c) Blackish growth of Mucor in the culture, (d) CT scan of the abdomen showing the exposed kidney after debridement, (e) SSG over the debrided woundThe present patient developed signs of infection at 1 week after transplant, and he had several risk factors for mucormycosis including chronic kidney disease, long-term diabetes mellitus, kidney transplant, and immunosuppressive therapy. The treatment of cutaneous mucormycosis involves surgical debridement and treatment with liposomal amphotericin B.[1-3] The patient received liposomal amphotericin B for 14 days. The CT imaging showed a thin layer between the graft and outside environment due to deep debridement, which was the key to eradicate the cutaneous mucormycosis. The patient needed daily dressing with silver nitrate and antibacterial lotion. Due to the deep nature of the wound, antifungal therapy was decided to be continued. Isuvaconazole was preferred as it has less interaction with tacrolimus, sustained drug levels with better pharmacokinetic profile and better absorption. It is a new triazole antifungal approved for use in aspergillosis and mucormycosis.[4] Although cost is an issue with this drug, it has good results in case reports. There are not many reports of successful treatment of cutaneous mucormycosis with Isavuconazole in renal transplant recipients. There is a report on successful treatment of gastric mucormycosis with isavuconazole in renal transplant patient. Our patient tolerated the drug with least interaction with tacrolimus. More experience is needed with this drug for the treatment of Mucormycosis in solid organ transplant recipients. This letter is to make aware of the drug isavuconazole with least interaction to tacrolimus as a treatment for mucormycosis. Declaration of patient consent The authors certify that patient consent has been taken for participation in the study and for publication of clinical details and images. Patients understand that the names, initials would not be published, and all standard protocols will be followed to conceal their identity. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Zitieren
APA
Kirushnan, B., Balasubramaniyam, R., Ramesh, A., Jeevagan, M., & Balakrishnan, V. (2023). Successful Treatment of Cutaneous Mucormycosis after Renal Transplantation by Debridement, Liposomal Amphotericin B, and Isavuconazole. Indian Journal of Transplantation, 17(4), 470-471. https://doi.org/10.4103/ijot.ijot_67_23
Vancouver
Kirushnan B, Balasubramaniyam R, Ramesh A, Jeevagan M, Balakrishnan V. Successful Treatment of Cutaneous Mucormycosis after Renal Transplantation by Debridement, Liposomal Amphotericin B, and Isavuconazole. Indian Journal of Transplantation. 2023;17(4):470-471. doi:10.4103/ijot.ijot_67_23
BibTeX
@article{Kirushnan2023,
author = {Kirushnan, Balaji and Balasubramaniyam, R and Ramesh, Anu and Jeevagan, M and Balakrishnan, Vijayalakshmi},
title = {Successful Treatment of Cutaneous Mucormycosis after Renal Transplantation by Debridement, Liposomal Amphotericin B, and Isavuconazole},
journal = {Indian Journal of Transplantation},
year = {2023},
volume = {17},
number = {4},
pages = {470--471},
doi = {10.4103/ijot.ijot_67_23}
}
EUVIMED